← Oncology Approval Tracker

FDA DECISION ·

Tudriqev + nivolumab

vusolimogene oderparepvec-wtpg with nivolumab · Replimune

Accelerated approvalNew therapyMelanoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with unresectable advanced cutaneous melanoma after progression on an anti-PD-1 antibody-based regimen.

LAMPGEN ANALYSIS

Why it matters

The approval adds an intratumoral oncolytic virus combination after PD-1 therapy. Separate response in the efficacy-evaluable subgroup from results across all trial participants.

What research teams should watch

Track injected and noninjected lesions, handling procedures and multidisciplinary injection capacity. Verify the confirmatory trial design before discussing comparative benefit.

PRIMARY RECORDS

Sources